Post Type Archives: News

Lonza, one of the world’s largest contract development and manufacturing organizations (CDMOs), announced the launch of TheraPEAK® AmpliCell® Cytokines and TheraPEAK® 293-GT® Medium to expand its GMP solutions for cell and gene therapy. Cytokines represent a critical component in cell therapy manufacturing, supporting the expansion and maintenance of living cells. TheraPEAK® AmpliCell® Cytokines enable the […]

Guala Closures, a global leader in specialty beverage closure solutions, announced the execution of an agreement to acquire KWK Kunststoffwerk Kremsmünster GmbH (“KWK”), a premier Austrian manufacturer of plastic caps & closures and precision dosing devices for the pharmaceutical and nutraceutical markets. Established in 1950 and headquartered in Kremsmünster, Austria, KWK serves an extensive portfolio […]

LOTTE BIOLOGICS (CEO James Park) announced that it has signed a Letter of Intent (LOI) for strategic business collaboration with a multinational biotechnology company headquartered in the United States. The partner’s innovative therapy, approved and launched in Japan ahead of other global markets, has shown strong clinical and commercial success. Several pipeline programs are also […]

Lonza, one of the world’s largest contract development and manufacturing organizations (CDMOs), announced today the operational readiness of its new aseptic drug product filling line in Stein (CH). The filling line was granted a GMP license following Swissmedic approval, strengthening Lonza’s existing capacity for liquid and lyophilized vial filling while introducing advanced containment technology to […]

Chiesi Group and Arbor Biotechnologies announced an exclusive global collaboration and license agreement aimed at developing treatments for rare liver diseases on October 6th. Per the terms of the agreement, Chisei will receive exclusive rights to develop Arbor’s clinical stage program ABO-101, a liver-directed gene editing treatment aimed at treating primary hyperoxaluria type 1, or […]

MOLCURE, a Japanese biotechnology company specializing in AI-driven drug discovery for antibodies and peptides, announced a multi-year strategic research agreement with Boehringer Ingelheim on October 7th. The deal will see Boehringer implement MOLCURE’s platform technology to speed discovery of antibody therapeutics for multiple undisclosed targets. Financial details of the partnership were undisclosed. According to a […]

Axplora, a global leader in small molecule API manufacturing and a trusted partner to the world’s most innovative pharmaceutical companies, announced that the total investments initiated across its global network in 2025 will exceed €100 million. This commitment underscores Axplora’s determination to accelerate growth, strengthen capabilities, and reinforce its position at the forefront of pharmaceutical […]

Symbiosis Pharmaceutical Services (Symbiosis), a global contract manufacturing organisation (CMO) specialising in the sterile manufacture of injectable drug products, has successfully completed qualification of its new FPD 50 Flexicon automated fill/finish line at its new commercial production facility in Stirling, Scotland. The fully integrated sterile liquid fill/finish system operates under a Grade A Restricted Access […]

Lonza, one of the world’s largest contract development and manufacturing organizations (CDMOs), announced the launch of TheraPEAK® AmpliCell® Cytokines and TheraPEAK® 293-GT® Medium to expand its GMP solutions for cell and gene therapy. Cytokines represent a critical component in cell therapy manufacturing, supporting the expansion and maintenance of living cells. TheraPEAK® AmpliCell® Cytokines enable the reliable expansion, […]

Owlstone Medical (“Owlstone”), the global leader in Breath Biopsy® for applications in early disease detection and precision medicine, today announced that it has won an award of up to $49.1 million from the Advanced Research Projects Agency for Health (ARPA-H) for the Platform Optimizing SynBio for Early Intervention and Detection in Oncology (POSEIDON) program. POSEIDON […]